PolitiKit

Market access for beef and cattle, achieving new and defending existing trade agreements.

Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry

We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).

Artificial Intelligence: Demonstrate leadership in AI by providing financial support for the Health Artificial Intelligence Validation Network (HAIVN) to improve the evaluation and regulation of AI in Canada as part of Health Canada’s Medical Devices Directorate regulatory process, for the purpose of improved healthcare, economic development and innovation in Canada.

Health policy regarding the Natural Health Product Regulations, food and drug regulations, supplemented food regulations, the Prescription Drug List, the safe food for Canadians Act, Cannabis Act, Protecting Canadians from Unsafe Drugs Act, and the Food and Drug Act.

Advocating for implementation of Canada's drugs for rare diseases strategy.

Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.

Data as it relates to all health and cancer data policy, planning and outcomes.

Canadian Partnership Against Cancer, as it relates to continued federal funding & long term investment in health research through Canadian Institutes of Health Research.

Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Provide input on a national strategy for drugs for rare diseases.

Provide input on pharmacare.

Recommend the creation of a Chief Patient Officer.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Recommend the creation of a Patient Ombudsman.

Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.

Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.

Support input into the consultation on draft guidance on decentralized clinical trials.

Support input regarding Canada’s pharmaceutical sovereignty.

Seek assurances the federal government will not implement a flavor ban on the regulated Canadian Vaping Industry. Furthermore, encourage the implementation of all current regulations.

Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.

Issues related to U.S. pharmaceutical importation, trade and policies, including research and development, regulatory authorizations, funding of medicines, supply sources and supply chains.

Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy.

Federally-funded public drug plans, with respect to reimbursement for medicines for federal plan beneficiaries.

Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases.

Issues related to U.S. pharmaceutical importation, trade and policies, including research and development, regulatory authorizations, funding of medicines, supply sources and supply chains.

Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

Federally-funded public drug plans, with respect to reimbursement for medicines for federal plan beneficiaries.

Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.

Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases.

Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.

Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Implementation of Canada's action plan for pain and federal initiatives related to pain management.

Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases

Regulations and legislation related to beef cattle and meat production, exports and imports.

Farm policy and programs with respect to business risk management, innovation, environment, etc.

Discussion of items in pre-budget submission.

SENIORS: Ensuring that all vulnerable seniors (including those living independently in their communities and those living in long-term care homes) have access to necessary and appropriate oral health care to age in wellness and with dignity.

DENTAL CARE FOR CANADIANS: Recommendations to support the delivery of the Canada Dental Benefit, Canada Dental Care Plan (Budget 2023), Oral Health Access Fund (Budget 2023), and Investments in Better Dental Care Data (Statistics Canada).

ACCES TO ORAL HEALTH CARE: Improved access to preventive oral health care services for millions of vulnerable people across Canada (emphasis on children, seniors aging in communities and in long-term care, people with disabilities, rural and remote communities, Indigenous communities, low-income households).

CANADA’S HEALTH CARE WORKFORCE: Addressing Canada’s health workforce crisis, including but not limited to incentives and supports to increase recruitment and retention within the health workforce generally, and to address the rural and remote health workforce specifically.